Martel Rachel A, Lee Mabel B, Schadwell Alessia, Siavoshi Mehrnaz, Kwan Lorna, Miller Jenna, Leonard Chelsea, Roman Robert A, Armstrong Abigail, Kroener Lindsay
Department of Obstetrics and Gynecology, University of California, Los Angeles, California.
Department of Obstetrics and Gynecology, University of California, Los Angeles, California.
Fertil Steril. 2024 Dec;122(6):993-1001. doi: 10.1016/j.fertnstert.2024.07.030. Epub 2024 Jul 26.
To compare aneuploidy rates among in vitro fertilization (IVF) cycles using preimplantation genetic testing for monogenic disorders (PGT-M) and aneuploidy (PGT-A) compared with IVF cycles using PGT-A alone, and to determine the likelihood of obtaining at least one usable embryo in cycles using PGT-M+PGT-A compared with cycles using PGT-A alone.
Retrospective cohort study.
Single genetics laboratory.
PATIENT(S): All IVF cycles for patients aged 18-45 undergoing PGT-A with or without concurrent PGT-M at a single genetics laboratory from November 2019 to March 2023.
INTERVENTION(S): Use of PGT-M+PGT-A vs. use of PGT-A alone.
MAIN OUTCOME MEASURE(S): Per cycle aneuploidy rate stratified by age, and per cycle likelihood of obtaining at least one usable embryo stratified by age and inheritance pattern of monogenic disease.
RESULT(S): A total of 72,522 IVF cycles were included; 4,255 cycles (5.9%) using PGT-M+PGT-A and 68,267 cycles (94.1%) using PGT-A alone. The PGT-M+PGT-A group was younger than the PGT-A alone group (<35 years old: 56.1% vs. 30.5%). The majority of PGT-M cycles were performed for autosomal dominant pathogenic variants (42.4%), followed by autosomal recessive (36.5%), X-linked dominant (13.3%), and X-linked recessive (7.5%). The median number of embryos biopsied was higher in PGT-A alone compared with PGT-M+PGT-A cycles for patients aged <35, but it was equivalent in all other age groups. Age stratified aneuploidy rates did not significantly differ between PGT-M+PGT-A compared with PGT-A alone cycles. The probability of having a usable embryo declined with increasing age across all inheritance patterns. Compared with PGT-A alone, PGT-M+PGT-A cycles for patients aged ≤40 across all inheritance patterns were significantly less likely to yield a usable embryo, except in cycles for autosomal recessive diseases in the 38-40 age group and X-linked recessive diseases in the 35-37 age group. There were no consistent differences seen between groups in patients over 40. Cycles for patients with autosomal dominant diseases had the lowest likelihood of yielding a usable embryo for patients aged <43.
CONCLUSION(S): In vitro fertilization cycles using PGT-M+PGT-A have similar age-specific aneuploidy rates to those using PGT-A alone. Cycles for patients ≤40 using PGT-M+PGT-A are significantly less likely to yield a usable embryo compared with those using PGT-A alone.
比较使用单基因疾病植入前基因检测(PGT-M)和非整倍体检测(PGT-A)的体外受精(IVF)周期与仅使用PGT-A的IVF周期之间的非整倍体率,并确定与仅使用PGT-A的周期相比,使用PGT-M+PGT-A的周期获得至少一个可用胚胎的可能性。
回顾性队列研究。
单一遗传学实验室。
2019年11月至2023年3月在单一遗传学实验室接受PGT-A(无论是否同时进行PGT-M)的18至45岁患者的所有IVF周期。
使用PGT-M+PGT-A与仅使用PGT-A。
按年龄分层的每个周期非整倍体率,以及按年龄和单基因疾病遗传模式分层的每个周期获得至少一个可用胚胎的可能性。
共纳入72522个IVF周期;4255个周期(5.9%)使用PGT-M+PGT-A,68267个周期(94.1%)仅使用PGT-A。PGT-M+PGT-A组比仅使用PGT-A组年轻(<35岁:56.1%对30.5%)。大多数PGT-M周期是针对常染色体显性致病变异进行的(42.4%),其次是常染色体隐性(36.5%)、X连锁显性(13.3%)和X连锁隐性(7.5%)。对于<35岁的患者,仅使用PGT-A时活检的胚胎中位数高于使用PGT-M+PGT-A的周期,但在所有其他年龄组中两者相当。与仅使用PGT-A的周期相比,PGT-M+PGT-A周期按年龄分层的非整倍体率无显著差异。在所有遗传模式中,获得可用胚胎的概率随年龄增加而下降。与仅使用PGT-A相比,所有遗传模式下年龄≤40岁的患者使用PGT-M+PGT-A的周期产生可用胚胎的可能性显著降低,但38-40岁年龄组的常染色体隐性疾病周期和35-37岁年龄组的X连锁隐性疾病周期除外。40岁以上患者组之间未观察到一致差异。对于<43岁的常染色体显性疾病患者,其周期产生可用胚胎的可能性最低。
使用PGT-M+PGT-A的体外受精周期与仅使用PGT-A的周期具有相似的年龄特异性非整倍体率。与仅使用PGT-A的周期相比,年龄≤40岁的患者使用PGT-M+PGT-A的周期产生可用胚胎的可能性显著降低。